Sendai virus F glycoprotein induces IL‐6 production in dendritic cells in a fusion‐independent manner

  title={Sendai virus F glycoprotein induces IL‐6 production in dendritic cells in a fusion‐independent manner},
  author={Hayato Suzuki and Masayuki Kurooka and Yoko Hiroaki and Yoshinori Fujiyoshi and Yasufumi Kaneda},
  journal={FEBS Letters},
We previously reported that inactivated Sendai virus particle (hemagglutinating virus of Japan envelope; HVJ‐E) has anti‐tumor effects by eliciting IL‐6 production in dendritic cells (DCs). In the present study, we investigated which components of HVJ‐E elicit IL‐6 production. HVJ‐E containing F0 protein inactive for virus envelope–cell membrane fusion enhanced IL‐6 production. Reconstituted liposomes containing F protein stimulated IL‐6 production. The antibody against F protein inhibited IL‐6… 
Cancer immunotherapy using the Fusion gene of Sendai virus
It is found that F plasmid treatment resulted in a significant increase in the secretion of the chemokine RANTES by tumour-infiltrating T cells, which means F gene therapy may show promise as a novel therapeutic for single or combined cancer immunotherapy.
Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-γ Production
IL-12–conjugated HVJ-E is a promising tool for the treatment of cancers, including lung metastasis by inducing local production of IFN-γ in the lungs and generating large numbers of melanoma-specific CTLs.
A New Approach to Castration-Resistant Prostate Cancer Using Inactivated Virus
HVJ-E therapy could be an innovative immune therapy for prostate cancer with an acceptable safety profile and treatment for CRPC patients was feasible, and the PSA levels of a subgroup of patients responded.
Hemagglutinating virus of Japan envelope (HVJ-E) can enhance the immune responses of swine immunized with killed PRRSV vaccine.
The results suggest that HVJ-E could be employed as an effective adjuvant to enhance the humoral and cellular responses of piglets to PRRSV.
Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration‐resistant prostate cancer
An open‐label, phase I, dose‐escalation study in patients with castration‐resistant prostate cancer to determine the safety and efficacy of intratumoral and s.c. injections of GEN0101 found it well‐tolerated and feasible to use.
A Novel Therapy for Melanoma and Prostate Cancer Using a Non-Replicating Sendai Virus Particle (HVJ-E)
Deletion mutants of oncolytic viruses, and recombinant viruses carrying a therapeutic gene that induce cancer apoptosis or cancer immunity have been developed and evaluated in the clinical setting.
Syncytia Formation in Oncolytic Virotherapy
The purpose of this review is to examine the existing body of literature on syncytia formation in oncolytics and offer direction for potential future studies.
Virosome: a novel vector to enable multi-modal strategies for cancer therapy.
  • Y. Kaneda
  • Biology, Medicine
    Advanced drug delivery reviews
  • 2012
A promising multi-modal cancer therapy will be achieved when virosomes with intrinsic anti-Tumor activities are utilized as vectors for the delivery of anti-tumor drugs and genes.
Oncolytic Sendai virus-based virotherapy for cancer: recent advances
Sendai virus-based virotherapy and its anticancer mechanisms are introduced, which are different from those of the conventional oncolytic viruses that kill cancer cells by cancer cell-selective replication.


Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
This is the first report to show that HVJ-E alone can eradicate tumors and the mechanism through which it induces antitumor immune responses and shows promise as a novel therapeutic for cancer immunotherapy.
Sendai virus-induced cell fusion.
  • Y. Okada
  • Biology, Medicine
    Methods in enzymology
  • 1993
It is discussed that Ehdich ascites tumor cells are rapidly fused by HVJ at 37 °, under conditions supplying calcium ions and allowing energy generation, and the initial reaction is disruption of the plasma membranes.
Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation
It is reported that inactivated, replication-defective Sendai virus particles (HVJ-E) also has an antitumor effect through non-T cell immunity, and injection caused systemic activation of NK cells and enhanced their cytotoxity against tumor cells.
TLR-Independent Induction of Dendritic Cell Maturation and Adaptive Immunity by Negative-Strand RNA Viruses1
The data presented here provide evidence for the existence of a novel intracellular pathway independent of TLR-mediated signaling responsible for live virus triggering of DC maturation and demonstrate its critical role in the onset of antiviral immunity.
Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses.
A strong correlation between DC maturation and the ability of the virus to induce type I IFN synthesis was demonstrated, and separate pathways for the induction of cytokine secretion and the up-regulation of major histocompatibility complex and costimulatory molecules were activated.
Sendai virus internal fusion peptide: structural and functional characterization and a plausible mode of viral entry inhibition.
It is found that SV-201 and its elongated form, SV-197, are highly potent in inducing fusion of the highly stable large unilamellar vesicles composed of egg phosphatidylcholine, a property found only in an extended version of the HIV-1 fusion peptide.
Glycoproteins of Sendai virus (HVJ) have a critical ratio for fusion between virus envelopes and cell membranes.
It was found that for maximum cytotoxic activity of the vesicles, there was an optimal ratio of F to HN of two, which suggests that HN is not merely the initial binding site to the cell surface, and that interactions between HN and F proteins on the virus surface may be important for the biological activities of these proteins onThe cells.
Reconstituted fusion liposomes for gene transfer in vitro and in vivo
HVJ-liposomes that are efficient in vitro and in vivo gene delivery vehicles based on cell fusion properties of the Sendai virus are developed, although replication of the viral genome is severely impaired by prior UV-irradiation of HVJ particles.
Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system.
HVJ envelope vector will be useful for both ex vivo and in vivo gene therapy experiments, and efficiency of gene transfer was greatly enhanced by protamine sulfate and centrifugation.
Selective extraction of biologically active F‐glycoprotein from dithiothreitol reduced sendai virus particles
An efficient, simple and quick new method for obtaining high quantities of Sendai virus F-glycoprotein is described, which involves reduction of this glycoprotein into bilayers of phospholipids.